Twist Bioscience (NASDAQ:TWST) Releases Quarterly Earnings Results

Twist Bioscience (NASDAQ:TWST) announced its earnings results on Thursday. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05, Briefing.com reports. Twist Bioscience had a negative return on equity of 30.81% and a negative net margin of 69.24%. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same period last year, the business posted ($1.06) EPS. The company’s revenue was up 25.1% on a year-over-year basis.

Twist Bioscience Stock Performance

Twist Bioscience stock traded up $9.20 during trading on Friday, hitting $41.21. The company’s stock had a trading volume of 4,458,430 shares, compared to its average volume of 909,964. The stock’s fifty day moving average is $34.03 and its 200 day moving average is $30.96. Twist Bioscience has a 1-year low of $11.81 and a 1-year high of $43.21.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th. Evercore ISI boosted their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday. Robert W. Baird boosted their target price on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday. Barclays boosted their price target on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Scotiabank boosted their price target on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a report on Monday, February 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $41.67.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,487 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the transaction, the chief executive officer now directly owns 516,409 shares in the company, valued at $19,329,188.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Patrick John Finn sold 2,174 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the sale, the chief operating officer now owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 1,487 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the sale, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,211 shares of company stock worth $449,573. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.